----------------------------------------------
------------------------------------------------------------------
Coronary events are currently the leading cause of death among men and women. In fact, these are often the most common deaths of people in the United States. While most often coronary conditions are treated through lifestyle changes such as ceasing smoking, losing weight, lowering blood pressure, medications or surgeries, other treatments such as oral chelation therapy are on the rise.
In this type of therapy, an ethylene diamine tetra-acetic acid or EDTA solution, not yet approved by the United States Food and Drug Administration is often used to provide relief. Even without such approval, a study in 2007 showed that there were over 10,000 people in the United States opting for this treatment. Ultimately, the substance provides a chemical process using molecules to bind and hold metals and minerals in the body in place.
Originally used to eliminate excess waste and toxic metals from the body, the treatment is far from new. For, EDTA has also been used to eliminate iron overload and treat lead poisoning in Western medicine. Whereas, when using the process to treat heart disease, a health care provider carefully provides injections of disodium EDTA into the veins over the course of 30 or more infusions generally on a weekly basis. After which, the treatment moves to a maintenance phase in which infusions are provided on an as needed basis.
To help determine whether this therapy might be helpful in treating heart attack victims, two organizations supported a trial. The purpose of the trial, to determine the success rate of the therapy on individuals with a previous history of heart attacks and heart disease. The results showed that the infusions were successful in dropping the number of occurrences, though only in people whom were also diabetic.
As only 1/3 of the participants were known to have diabetes, the results varied. However, in most cases, these individuals showed a 41 percent drop in cardiovascular events, a 40% risk of death due to coronary events, stroke and non-fatal heart attacks. Participants in this group also showed a 52% percent drop in repetitive heart attacks and a 43% drop in deaths from non-related causes. Whereas, most individuals whom did not have diabetes reported no significant benefits from having received the infusions.
The study also looked at individuals taking high dose minerals and vitamins along with the infusions. In most cases, the study showed that the combination provided the most reduction in risk of heart attacks versus the individuals whom were only given placebos during the trial.
Sixteen percent of individuals receiving chelation therapy and fifteen percent provided placebos during the trial halted the injections due to complications. The results included four major events, including two deaths, one death in the placebo group and one in the chelation group. To date, the most prominent side effect appears to be a burning sensation at the injection site during the infusion.
More research is needed before it can be determined if chelation therapy provides the best treatment for heart attack victims, especially those living with diabetes. As a result, the results reflected in this article or current research studies do not provide enough detailed information in order to make a final decision. Regardless, researchers and scientists are hopeful that future studies and trials will provide more positive results.
In this type of therapy, an ethylene diamine tetra-acetic acid or EDTA solution, not yet approved by the United States Food and Drug Administration is often used to provide relief. Even without such approval, a study in 2007 showed that there were over 10,000 people in the United States opting for this treatment. Ultimately, the substance provides a chemical process using molecules to bind and hold metals and minerals in the body in place.
Originally used to eliminate excess waste and toxic metals from the body, the treatment is far from new. For, EDTA has also been used to eliminate iron overload and treat lead poisoning in Western medicine. Whereas, when using the process to treat heart disease, a health care provider carefully provides injections of disodium EDTA into the veins over the course of 30 or more infusions generally on a weekly basis. After which, the treatment moves to a maintenance phase in which infusions are provided on an as needed basis.
To help determine whether this therapy might be helpful in treating heart attack victims, two organizations supported a trial. The purpose of the trial, to determine the success rate of the therapy on individuals with a previous history of heart attacks and heart disease. The results showed that the infusions were successful in dropping the number of occurrences, though only in people whom were also diabetic.
As only 1/3 of the participants were known to have diabetes, the results varied. However, in most cases, these individuals showed a 41 percent drop in cardiovascular events, a 40% risk of death due to coronary events, stroke and non-fatal heart attacks. Participants in this group also showed a 52% percent drop in repetitive heart attacks and a 43% drop in deaths from non-related causes. Whereas, most individuals whom did not have diabetes reported no significant benefits from having received the infusions.
The study also looked at individuals taking high dose minerals and vitamins along with the infusions. In most cases, the study showed that the combination provided the most reduction in risk of heart attacks versus the individuals whom were only given placebos during the trial.
Sixteen percent of individuals receiving chelation therapy and fifteen percent provided placebos during the trial halted the injections due to complications. The results included four major events, including two deaths, one death in the placebo group and one in the chelation group. To date, the most prominent side effect appears to be a burning sensation at the injection site during the infusion.
More research is needed before it can be determined if chelation therapy provides the best treatment for heart attack victims, especially those living with diabetes. As a result, the results reflected in this article or current research studies do not provide enough detailed information in order to make a final decision. Regardless, researchers and scientists are hopeful that future studies and trials will provide more positive results.
About the Author:
When you are looking for information about oral chelation, come to our web pages today. More details are available at http://www.heartdrop.com now.
0 comments:
Post a Comment